GlassScriptPhysician profile
Nely Ochoa Oliveros
NPI 1306664677
$2,142.88
in general payments reported to CMS, 2019-2025
11 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $169 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319 · Travel and Lodging: $740 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.61 |
| Travel and Lodging | $740.27 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $826.90 | 2025 | Interstim |
| Abbvie INC. | $679.51 | 2024-2025 | |
| Madrigal Pharmaceuticals | $196.94 | 2024-2025 | Rezdiffra |
| Janssen Biotech, INC. | $118.69 | 2025 | Tremfya, Simponi, Simponi Aria |
| Aimmune Therapeutics, INC. | $76.40 | 2025 | Zenpep |
| Amgen INC. | $70.28 | 2025 | Uplizna |
| Novo Nordisk INC | $58.10 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $41.56 | 2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $30.39 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.76 | 2025 | Xifaxan |
| Vivus LLC | $19.35 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nely Ochoa Oliveros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.